{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:46:33Z","timestamp":1775029593065,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Multiple Sclerosis Society of Canada, Consortium of Multiple Sclerosis Centers"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is characterized by chronic inflammation of the central nervous system (CNS), particularly the optic nerves and spinal cord. Although it displays some clinical features similar to multiple sclerosis (MS), the etiology and treatment are distinct, and therefore accurate diagnosis is essential. Autoantibodies targeting the water channel protein aquaporin-4 (AQP4) and the myelin sheath protein myelin oligodendrocyte glycoprotein are the major antigen-specific serological biomarkers known to date, with destruction of astrocytes as the primary mode of CNS damage in AQP4-positive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Content<\/jats:title><jats:p>This mini-review summarizes the pathobiology, clinical features, and current methods of serological testing used to assess NMOSD and differentiate this disorder from MS. A brief summary of emerging therapies is also presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>NMOSD can be distinguished from MS through a combination of clinical findings, imaging investigations, and serological analysis. Seronegative cases are particularly difficult to diagnose and can pose a challenge to clinicians. As knowledge deepens, new therapies and biomarkers are expected to improve treatment of this rare debilitating disease.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jalm\/jfab150","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:10:53Z","timestamp":1637669453000},"page":"305-310","source":"Crossref","is-referenced-by-count":10,"title":["Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-8296","authenticated-orcid":false,"given":"Clare","family":"Fiala","sequence":"first","affiliation":[{"name":"Laboratory Medicine Program, Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Rotstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Division of Neurology, Unity Health Toronto (St. Michael\u2019s Hospital), Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D","family":"Pasic","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unity Health Toronto (St. Joseph\u2019s Health Centre), Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2022010916495475400_jfab150-B1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","article-title":"Diagnosis and management of neuromyelitis optica spectrum disorders\u2014an update","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2022010916495475400_jfab150-B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflamm"},{"key":"2022010916495475400_jfab150-B3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"2022010916495475400_jfab150-B4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s12264-020-00525-3","article-title":"Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside","volume":"36","author":"Zhu","year":"2020","journal-title":"Neurosci Bull"},{"key":"2022010916495475400_jfab150-B5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Multiple Scler Relat Disord"},{"key":"2022010916495475400_jfab150-B6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"2022010916495475400_jfab150-B7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"2022010916495475400_jfab150-B8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"2022010916495475400_jfab150-B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jns.2009.04.039","article-title":"Environmental changes and epidemiology of multiple sclerosis in the French West Indies","volume":"286","author":"Cabre","year":"2009","journal-title":"J Neurol Sci"},{"key":"2022010916495475400_jfab150-B10","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00415-013-6926-y","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J Neurol"},{"key":"2022010916495475400_jfab150-B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2012.08.032","article-title":"Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan","volume":"323","author":"Houzen","year":"2012","journal-title":"J Neurol Sci"},{"key":"2022010916495475400_jfab150-B12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"2022010916495475400_jfab150-B13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"2022010916495475400_jfab150-B14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"key":"2022010916495475400_jfab150-B15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.neuroscience.2004.08.049","article-title":"Anchoring of aquaporin-4 in brain: Molecular mechanisms and implications for the physiology and pathophysiology of water transport","volume":"129","author":"Amiry-Moghaddam","year":"2004","journal-title":"Neuroscience"},{"key":"2022010916495475400_jfab150-B16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jneuroim.2009.04.001","article-title":"Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica","volume":"211","author":"Tani","year":"2009","journal-title":"J Neuroimmunol"},{"key":"2022010916495475400_jfab150-B17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"2022010916495475400_jfab150-B18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"2022010916495475400_jfab150-B19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"2022010916495475400_jfab150-B20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity"},{"key":"2022010916495475400_jfab150-B21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2022010916495475400_jfab150-B22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2009.04.004","article-title":"Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica","volume":"9","author":"Saikali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2022010916495475400_jfab150-B23","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J Biol Chem"},{"key":"2022010916495475400_jfab150-B24","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"2022010916495475400_jfab150-B25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"2022010916495475400_jfab150-B26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"key":"2022010916495475400_jfab150-B27","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"2022010916495475400_jfab150-B28","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"2022010916495475400_jfab150-B29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"2022010916495475400_jfab150-B30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(02)00043-6","article-title":"Devic\u2019s neuromyelitis optica: clinical, laboratory, MRI and outcome profile","volume":"197","author":"de Seze","year":"2002","journal-title":"J Neurol Sci"},{"key":"2022010916495475400_jfab150-B31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/1352458504ms988oa","article-title":"Oligoclonal bands in Devic\u2019s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations","volume":"10","author":"Bergamaschi","year":"2004","journal-title":"Mult Scler"},{"key":"2022010916495475400_jfab150-B32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","article-title":"Clinical, CSF, and MRI findings in Devic\u2019s neuromyelitis optica","volume":"60","author":"O'Riordan","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022010916495475400_jfab150-B33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/01.wnl.0000256820.26489.17","article-title":"High CSF neurofilament heavy chain levels in neuromyelitis optica","volume":"68","author":"Miyazawa","year":"2007","journal-title":"Neurology"},{"key":"2022010916495475400_jfab150-B34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"2022010916495475400_jfab150-B35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2012.06.002","article-title":"Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry","volume":"320","author":"Jarius","year":"2012","journal-title":"J Neurol Sci"},{"key":"2022010916495475400_jfab150-B36","year":"2018"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/305\/42084147\/jfab150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/305\/42084147\/jfab150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T21:49:23Z","timestamp":1726177763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/7\/1\/305\/6498245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab150","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}